

Bibliografia del libro “L’importanza della Vitamina C”

1. Gava, R. *La Medicina che vorrei. Personalizzata, Integrata e Umanizzata*. (Edizioni Salus Infirmorum, 2019).
2. ISPRA. *Rapporto nazionale pesticidi nelle acque. Dati 2015-2016*. http://www.isprambiente.gov.it/files/2018/pubblicazioni/rapporti/Rapporto_282_2018.pdf (2018).
3. Pollution (Water, Air, Chemicals) - Food Empowerment Project. <https://foodispower.org/pollution-water-air-chemicals/>.
4. The President’s Cancer Panel. *Reducing Environmental Cancer Risk: What We Can Do Now*. https://deainfo.nci.nih.gov/Advisory/pcp/annualReports/pcp08-09rpt/PCP_Report_08-09_508.pdf (2010).
5. Walker, P., Rhubart-Berg, P., McKenzie, S., Kelling, K. & Lawrence, R. S. Public health implications of meat production and consumption. *Public Health Nutr.* **8**, 348–356 (2005).
6. Horrigan, L., Lawrence, R. S. & Walker, P. How sustainable agriculture can address the environmental and human health harms of industrial agriculture. *Environmental Health Perspectives* vol. 110 445–456 (2002).
7. Thomas, D. The mineral depletion of foods available to us as a nation (1940-2002) - A review of the 6th Edition of McCance and Widdowson. in *Nutrition and Health* vol. 19 21–55 (A B Academic Publishers, 2007).
8. Chaparro, C. M. & Dewey, K. G. Use of lipid-based nutrient supplements (LNS) to improve the nutrient adequacy of general food distribution rations for vulnerable sub-groups in emergency settings. *Matern. Child Nutr.* **6**, 1–69 (2010).
9. Maggini, S. Feeding the immune system: the role of micronutrients in restoring resistance to infections. *CAB Rev. Perspect. Agric. Vet. Sci. Nutr. Nat. Resour.* **3**, (2008).
10. Huskisson, E., Maggini, S. & Ruf, M. The Role of Vitamins and Minerals in Energy Metabolism and Well-Being. *J. Int. Med. Res.* **35**, 277–289 (2007).

Per maggiori informazioni sul libro

<https://www.robortogava.it/libri/importanza-vitamina-c>

11. Hemilä, H. & Louhiala, P. Vitamin C may affect lung infections. *J. R. Soc. Med.* **100**, 495–498 (2007).
12. Drouin, G., Godin, J.-R. & Pagé, B. The genetics of vitamin C loss in vertebrates. *Curr. Genomics* **12**, 371–8 (2011).
13. Colunga Biancatelli, R. M. L., Berrill, M. & Marik, P. E. The antiviral properties of vitamin C. *Expert Review of Anti-Infective Therapy* vol. 18 99–101 (2020).
14. Maeda, N. *et al.* Aortic wall damage in mice unable to synthesize ascorbic acid. *Proc. Natl. Acad. Sci. U. S. A.* **97**, 841–846 (2000).
15. Conney, A. H., Bray, G. A., Evans, C. & Burns, J. J. Metabolic Interactions Between L-Ascorbic Acid and Drugs. *Ann. N. Y. Acad. Sci.* **92**, 115–127 (1961).
16. Pauling, L. Evolution and the need for ascorbic acid. *Proc. Natl. Acad. Sci. U. S. A.* **67**, 1643–8 (1970).
17. Milton, K. Micronutrient intakes of wild primates: are humans different? *Comp. Biochem. Physiol. A. Mol. Integr. Physiol.* **136**, 47–59 (2003).
18. Padayatty, S. J. *et al.* Vitamin C pharmacokinetics: implications for oral and intravenous use. *Ann. Intern. Med.* **140**, 533–537 (2004).
19. Cameron, E. & Campbell, A. The orthomolecular treatment of cancer II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. *Chem. Biol. Interact.* **9**, 285–315 (1974).
20. Riordan, N. H., Riordan, H. D., Meng, X., Li, Y. & Jackson, J. A. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. *Med. Hypotheses* **44**, 207–213 (1995).
21. Hickey, S. & Roberts, H. *Ascorbate: The Science of Vitamin C*. vol. 1 (LULU, 2004).
22. Padayatty, S. J. & Levine, M. Vitamin C: the known and the unknown and Goldilocks. *Oral Dis.* **22**, 463–493 (2016).
23. Levine, M. *et al.* Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. *Proc. Natl. Acad. Sci. U. S. A.* **93**, 3704–3709 (1996).
24. Institute of Medicine (US) Panel on Dietary Antioxidants and Related Compounds. *Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Dietary Reference*

- Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids* (National Academies Press, 2000). doi:10.17226/9810.
25. Weinstein, M., Babyn, P. & Zlotkin, S. An orange a day keeps the doctor away: scurvy in the year 2000. *Pediatrics* **108**, E55 (2001).
 26. Wang, A. H. & Still, C. Old world meets modern: a case report of scurvy. *Nutr. Clin. Pract.* **22**, 445–448 (2007).
 27. Levine, M., Rumsey, S. C., Daruwala, R., Park, J. B. & Wang, Y. Criteria and recommendations for vitamin C intake. *JAMA* **281**, 1415–1423 (1999).
 28. Hemilä, H. Vitamin C and Infections. *Nutrients* **9**, (2017).
 29. Fonorow, O. Unexpected Early Response in Oral Bioavailability of Ascorbic Acid. *Townsend Lett.* (2020).
 30. Cathcart, R. F. Vitamin C, titrating to bowel tolerance, anascorbemia, and acute induced scurvy. *Med. Hypotheses* **7**, 1359–1376 (1981).
 31. Hong, J. M., Kim, J. H., Kang, J. S., Lee, W. J. & Hwang, Y. il. Vitamin C is taken up by human T cells via sodium-dependent vitamin C transporter 2 (SVCT2) and exerts inhibitory effects on the activation of these cells in vitro. *Anat. Cell Biol.* **49**, 88–98 (2016).
 32. Deutsch, J. C. Dehydroascorbic acid. *J. Chromatogr. A* **881**, 299–307 (2000).
 33. Savini, I., Rossi, A., Pierro, C., Avigliano, L. & Catani, M. V. SVCT1 and SVCT2: Key proteins for vitamin C uptake. *Amino Acids* **34**, 347–355 (2008).
 34. Tsukaguchi, H. *et al.* A family of mammalian Na⁺-dependent L-ascorbic acid transporters. *Nature* **399**, 70–75 (1999).
 35. Kuo, S.-M., Tan, C.-H., Dragan, M. & Wilson, J. X. Endotoxin Increases Ascorbate Recycling and Concentration in Mouse Liver. *J. Nutr.* **135**, 2411–2416 (2005).
 36. Du, J., Cullen, J. J. & Buettner, G. R. Ascorbic acid: Chemistry, biology and the treatment of cancer. *Biochimica et Biophysica Acta - Reviews on Cancer* vol. 1826 443–457 (2012).
 37. Wilson, J. X. The physiological role of dehydroascorbic acid. *FEBS Letters* vol. 527 5–9 (2002).
 38. Corti, A., Casini, A. F. & Pompella, A. Cellular pathways for transport and efflux of ascorbate and dehydroascorbate. *Arch.*

- Biochem. Biophys.* **500**, 107–115 (2010).
39. Vera, J. C., Rivas, C. I., Zhang, R. H., Farber, C. M. & Golde, D. W. Human HL-60 myeloid leukemia cells transport dehydroascorbic acid via the glucose transporters and accumulate reduced ascorbic acid. *Blood* **84**, 1628–1634 (1994).
 40. Huang, J. *et al.* Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke. *Proc. Natl. Acad. Sci. U. S. A.* **98**, 11720–11724 (2001).
 41. Levine, M., Padayatty, S. J. & Espey, M. G. Vitamin C: A Concentration-Function Approach Yields Pharmacology and Therapeutic Discoveries. *Adv. Nutr.* **2**, 78–88 (2011).
 42. Jorge, J. D. *et al.* Pharmacokinetics of vitamin C: Insights into the oral and intravenous administration of ascorbate. *P. R. Health Sci. J.* **27**, 7–19 (2008).
 43. Rümelin, A., Humbert, T., Lühker, O., Drescher, A. & Fauth, U. Metabolic clearance of the antioxidant ascorbic acid in surgical patients. *J. Surg. Res.* **129**, 46–51 (2005).
 44. Mandl, J., Szarka, A. & Bánhegyi, G. Vitamin C: update on physiology and pharmacology. *Br. J. Pharmacol.* **157**, 1097–1110 (2009).
 45. Mohammed, B. M. *et al.* Vitamin C promotes wound healing through novel pleiotropic mechanisms. *Int. Wound J.* **13**, 572–584 (2016).
 46. Steiling, H. *et al.* Sodium-dependent vitamin C transporter isoforms in skin: Distribution, kinetics, and effect of UVB-induced oxidative stress. *Free Radic. Biol. Med.* **43**, 752–762 (2007).
 47. Englard, S. & Seifter, S. The Biochemical Functions of Ascorbic Acid. *Annu. Rev. Nutr.* **6**, 365–406 (1986).
 48. Lane, D. J. R. & Richardson, D. R. The active role of vitamin C in mammalian iron metabolism: Much more than just enhanced iron absorption! *Free Radic. Biol. Med.* **75**, 69–83 (2014).
 49. Jubiz, W. & Ramirez, M. Effect of vitamin C on the absorption of levothyroxine in patients with hypothyroidism and gastritis. *J. Clin. Endocrinol. Metab.* **99**, E1031–4 (2014).
 50. Pullar, J. M., Carr, A. C., Bozonet, S. M. & Vissers, M. C. M.

- High vitamin c status is associated with elevated mood in male tertiary students. *Antioxidants* **7**, (2018).
51. Kodama, M., Kodama, T., Murakami, M. & Kodama, M. Vitamin C infusion treatment enhances cortisol production of the adrenal via the pituitary ACTH route. *In Vivo* **8**, 1079–85.
 52. Barabutis, N., Khangoora, V., Marik, P. E. & Catravas, J. D. Hydrocortisone and Ascorbic Acid Synergistically Prevent and Repair Lipopolysaccharide-Induced Pulmonary Endothelial Barrier Dysfunction. *Chest* **152**, 954–962 (2017).
 53. RECOVERY Collaborative Group *et al.* Dexamethasone in Hospitalized Patients with Covid-19. *N. Engl. J. Med.* **384**, 693–704 (2021).
 54. Carr, A. C. & McCall, C. The role of vitamin C in the treatment of pain: New insights. *Journal of Translational Medicine* vol. 15 (2017).
 55. Carr, A. C. & Maggini, S. Vitamin C and Immune Function. *Nutrients* **9**, (2017).
 56. Vitamin c and amino acid metabolism. *J. Am. Med. Assoc.* **117**, 937–938 (1941).
 57. Minor, E. A., Court, B. L., Young, J. I. & Wang, G. Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine. *J. Biol. Chem.* **288**, 13669–13674 (2013).
 58. Blaschke, K. *et al.* Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. *Nature* **500**, 222–226 (2013).
 59. Zhang, T.-Y. & Meaney, M. J. Epigenetics and the Environmental Regulation of the Genome and Its Function. *Annu. Rev. Psychol.* **61**, 439–466 (2010).
 60. Myers, K. O., Ibrahimou, B., Yusuf, K. K., Mauck, D. E. & Salihu, H. M. The effect of maternal vitamin C intake on fetal telomere length. *J. Matern. neonatal Med.* 1–6 (2019) doi:10.1080/14767058.2019.1628940.
 61. Salihu, H. M. *et al.* Impact of intrauterine tobacco exposure on fetal telomere length. *Am. J. Obstet. Gynecol.* **212**, 205.e1–8 (2015).
 62. Oudemans-van Straaten, H. M., Spoelstra-de Man, A. M. E. & de Waard, M. C. Vitamin C revisited. *Critical Care* vol. 18

- (2014).
63. Carr, A. & Frei, B. Does vitamin C act as a pro-oxidant under physiological conditions? *FASEB J.* **13**, 1007–1024 (1999).
 64. May, J. M. & Qu, Z. C. Ascorbic Acid Prevents Oxidant-induced Increases in Endothelial Permeability. *Biofactors* **37**, 46 (2011).
 65. Bergsten, P. *et al.* Millimolar concentrations of ascorbic acid in purified human mononuclear leukocytes. Depletion and reaccumulation. *J. Biol. Chem.* **265**, 2584–2587 (1990).
 66. McNamara, R., Deane, A. M., Anstey, J. & Bellomo, R. Understanding the rationale for parenteral ascorbate (Vitamin C) during an acute inflammatory reaction: A biochemical perspective. *Crit. Care Resusc.* **20**, 174–179 (2018).
 67. White, L. A., Freeman, C. Y., Forrester, B. D. & Chappell, W. A. In vitro effect of ascorbic acid on infectivity of herpesviruses and paramyxoviruses. *J. Clin. Microbiol.* **24**, 527–531 (1986).
 68. Pauling, L. The significance of the evidence about ascorbic acid and the common cold. *Proceedings of the National Academy of Sciences of the United States of America* vol. 68 2678–2681 (1971).
 69. Chen, Q. *et al.* Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissue. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 13604–13609 (2005).
 70. Chen, Q. *et al.* Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. *Proc. Natl. Acad. Sci. U. S. A.* **104**, 8749–54 (2007).
 71. Lee, S. H., Oe, T. & Blair, I. A. Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. *Science* **292**, 2083–2086 (2001).
 72. Podmore, I. D. *et al.* Vitamin C exhibits pro-oxidant properties. *Nature* **392**, 559 (1998).
 73. Heuser, G. & Vojdani, A. Enhancement of natural killer cell activity and T and B cell function by buffered vitamin C in patients exposed to toxic chemicals: The role of protein kinase - C. *Immunopharmacol. Immunotoxicol.* **19**, 291–312 (1997).
 74. Jariwalla, R. J. *et al.* Suppression of influenza A virus nuclear

- antigen production and neuraminidase activity by a nutrient mixture containing ascorbic acid, green tea extract and amino acids. *Biofactors* **31**, 1–15 (2007).
75. Deryabin, P. G. *et al.* Effects of a nutrient mixture on infectious properties of the highly pathogenic strain of avian influenza virus A/H5N1. *Biofactors* **33**, 85–97 (2008).
 76. May, J. M. & Harrison, F. E. Role of vitamin C in the function of the vascular endothelium. *Antioxidants Redox Signal.* **19**, 2068–2083 (2013).
 77. Dey, S. & Bishayi, B. Killing of *S. aureus* in murine peritoneal macrophages by Ascorbic acid along with antibiotics Chloramphenicol or Ofloxacin: Correlation with inflammation. *Microb. Pathog.* **115**, 239–250 (2018).
 78. Leibovitz, B. & Siegel, B. V. Ascorbic Acid and the Immune Response. in *Diet and Resistance to Disease* vol. 135 1–25 (Springer US, 1981).
 79. Dahl, H. & Degré, M. The effect of ascorbic acid on production of human interferon and the antiviral activity in vitro. *Acta Pathol. Microbiol. Scand. B.* **84B**, 280–284 (1976).
 80. Sorice, A. *et al.* Ascorbic Acid: Its Role in Immune System and Chronic Inflammation Diseases. *Mini-Reviews Med. Chem.* **14**, 444–452 (2014).
 81. Mikirova, N., Rogers, A., Casciari, J. & Taylor, P. Effect of high dose intravenous ascorbic acid on the level of inflammation in patients with rheumatoid arthritis. *Mod. Res. Inflamm.* **01**, 26–32 (2012).
 82. Gao, X., Curhan, G., Forman, J. P., Ascherio, A. & Choi, H. K. Vitamin C intake and serum uric acid concentration in men. *J. Rheumatol.* **35**, 1853–1858 (2008).
 83. PDQ Integrative Alternative and Complementary Therapies Editorial Board. *High-Dose Vitamin C (PDQ®): Patient Version. PDQ Cancer Information Summaries* (2002).
 84. Calcutt, G. The formation of hydrogen peroxide during the autoxidation of ascorbic acid. *Experientia* **7**, 26 (1951).
 85. Frei, B. & Lawson, S. Vitamin C and cancer revisited. *Proceedings of the National Academy of Sciences of the United States of America* vol. 105 11037–11038 (2008).
 86. Riordan Clinic Research Institute. *The Riordan IVC Protocol*

- for Adjunctive Cancer Care Intravenous Ascorbate as a Chemotherapeutic and Biological Response Modifying Agent.* <http://www.doctoryourself.com/RiordanIVC.pdf> (2013).
87. Belin, S. *et al.* Antiproliferative effect of ascorbic acid is associated with the inhibition of genes necessary to cell cycle progression. *PLoS One* **4**, (2009).
 88. Gonzalez, C. A. *et al.* Diet and cancer prevention: Contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Eur. J. Cancer* **46**, 2555–2562 (2010).
 89. St. Sauver, J. L. *et al.* Associations Between C-Reactive Protein and Benign Prostatic Hyperplasia/Lower Urinary Tract Symptom Outcomes in a Population-based Cohort. *Am. J. Epidemiol.* **169**, 1281–1290 (2009).
 90. Ma, Y. *et al.* High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian Cancer and Reduced Toxicity of Chemotherapy. *Sci. Transl. Med.* **6**, 222ra18-222ra18 (2014).
 91. Asano, K. The influence of hypoxia and exercise on ascorbic acid metabolism. *Japanese J. Phys. Fit. Sport. Med.* **21**, 69–86 (1972).
 92. Dannenberg, A. M., Widerman, A. H. & Friedman, P. S. Ascorbic Acid in the Treatment of Chronic Lead Poisoning. *J. Am. Med. Assoc.* **114**, (1940).
 93. Prasse, C., von Gunten, U. & Sedlak, D. L. Chlorination of Phenols Revisited: Unexpected Formation of α,β -Unsaturated C4-Dicarbonyl Ring Cleavage Products. *Environ. Sci. Technol.* **54**, 826–834 (2020).
 94. Klenner, F. The Use of Vitamin C as an Antibiotic. https://www.seanet.com/~alexs/ascorbate/195x/klenner-fr-j_appl_nutr-1953-v6-p274.htm.
 95. Saul, A. S. China Treating Coronavirus COVID-19 with Intravenous Vitamin C. *Global Research* <https://www.global-research.ca/three-intravenous-vitamin-c-research-studies-approved-treating-covid-19/5705405> (2020).
 96. Marik, P. E., Kory, P., Varon, J., Iglesias, J. & Meduri, G. U. MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale. *Expert Rev. Anti. Infect. Ther.* **19**, 129–135 (2021).
 97. Bellavite, P. & Donzelli, A. Hesperidin and SARS-CoV-2: New

- light on the healthy function of citrus fruits. *Antioxidants* **9**, 1–18 (2020).
98. NIH. Vitamin C | COVID-19 Treatment Guidelines. <https://www.covid19treatmentguidelines.nih.gov/adjunctive-therapy/vitamin-c/> (2020).
 99. Calder, P. C. Nutrition, immunity and COVID-19. *BMJ Nutr. Prev. Heal.* **3**, 74–92 (2020).
 100. Holford, P. *et al.* Vitamin C-An Adjunctive Therapy for Respiratory Infection, Sepsis and COVID-19. *Nutrients* **12**, (2020).
 101. Jovic, T. H. *et al.* Could Vitamins Help in the Fight Against COVID-19? *Nutrients* **12**, 1–30 (2020).
 102. Corrao, S. Use of Ascorbic Acid in Patients With COVID 19. *ClinicalTrials.gov* <https://clinicaltrials.gov/ct2/show/NCT04323514> (2020).
 103. Hiedra, R. *et al.* The use of IV vitamin C for patients with COVID-19: a case series. *Expert Rev. Anti. Infect. Ther.* 1–3 (2020) doi:10.1080/14787210.2020.1794819.
 104. Boretti, A. & Banik, B. K. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. *PharmaNutrition* **12**, 100190 (2020).
 105. Marik, P. E., Khangoora, V., Rivera, R., Hooper, M. H. & Catravas, J. Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study. *Chest* **151**, 1229–1238 (2017).
 106. Spoelstra-de Man, A. M. E., Oudemans-van Straaten, H. M. & Elbers, P. W. G. Vitamin C and thiamine in critical illness. *BJA Educ.* **19**, 290–296 (2019).
 107. Schorah, C. J. *et al.* Total vitamin C, ascorbic acid, and dehydroascorbic acid concentrations in plasma of critically ill patients. *Am. J. Clin. Nutr.* **63**, 760–765 (1996).
 108. Blee, T. H., Cogbill, T. H. & Lambert, P. J. Hemorrhage associated with vitamin C deficiency in surgical patients. *Surgery* **131**, 408–412 (2002).
 109. Borrelli, E. *et al.* Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. *Crit. Care Med.* **24**, 392–397 (1996).

110. Polidori, M. C., Mecocci, P. & Frei, B. Plasma vitamin C levels are decreased and correlated with brain damage in patients with intracranial hemorrhage or head trauma. *Stroke* **32**, 898–902 (2001).
111. Ballmer, P. E. *et al.* Depletion of plasma vitamin C but not of vitamin E in response to cardiac operations. *J. Thorac. Cardiovasc. Surg.* **108**, 311–320 (1994).
112. Hume, R., Weyers, E., Rowan, T., Reid, D. S. & Hillis, W. S. Leucocyte ascorbic acid levels after acute myocardial infarction. *Heart* **34**, 238–243 (1972).
113. Rümelin, A. *et al.* Early postoperative substitution procedure of the antioxidant ascorbic acid. *J. Nutr. Biochem.* **16**, 104–108 (2005).
114. Evans, R. M., Currie, L. & Campbell, A. The distribution of ascorbic acid between various cellular components of blood, in normal individuals, and its relation to the plasma concentration. *Br. J. Nutr.* **47**, 473–482 (1982).
115. Fisher, B. J. *et al.* Mechanisms of attenuation of abdominal sepsis induced acute lung injury by ascorbic acid. *Am. J. Physiol. - Lung Cell. Mol. Physiol.* **303**, (2012).
116. Segal, A. W. How neutrophils kill microbes. *Annu. Rev. Immunol.* **23**, 197–223 (2005).
117. Akaike, T. Role of free radicals in viral pathogenesis and mutation. *Rev. Med. Virol.* **11**, 87–101 (2001).
118. Nualart, F. J. *et al.* Recycling of vitamin C by a bystander effect. *J. Biol. Chem.* **278**, 10128–10133 (2003).
119. Hosakote, Y. M. *et al.* Viral-mediated inhibition of antioxidant enzymes contributes to the pathogenesis of severe respiratory syncytial virus bronchiolitis. *Am. J. Respir. Crit. Care Med.* **183**, 1550–1560 (2011).
120. Hume, R. & Weyers, E. Changes in leucocyte ascorbic acid during the common cold. *Scott. Med. J.* **18**, 3–7 (1973).
121. Hemilä, H. & Louhiala, P. Vitamin C for preventing and treating pneumonia. *Cochrane Database Syst. Rev.* **2013**, CD005532 (2013).
122. Hunt, C., Chakravorty, N. K., Annan, G., Habibzadeh, N. & Schorah, C. J. The clinical effects of vitamin C supplementation in elderly hospitalised patients with acute respiratory infections.

- Int. J. Vitam. Nutr. Res.* **64**, 212–219 (1994).
123. Klenner, F. R. *Observations On the Dose and Administration of Ascorbic Acid When Employed Beyond the Range Of A Vitamin In Human Pathology*. Adobe Acrobat Journal of Applied Nutrition vol. 23 <https://yost.com/health/klenner/klenner-1971.pdf> (1971).
 124. Biesalski, H. K. Parenteral ascorbic acid in haemodialysis patients. *Curr. Opin. Clin. Nutr. Metab. Care* **11**, 741–746 (2008).
 125. Holley, A. D., Osland, E., Barnes, J., Krishnan, A. & Fraser, J. F. Scurvy: Historically a plague of the sailor that remains a consideration in the modern intensive care unit. *Intern. Med. J.* **41**, 283–285 (2011).
 126. Smith, A., Di Primio, G. & Humphrey-Murto, S. Scurvy in the developed world. *CMAJ* **183**, (2011).
 127. Raynaud-Simon, A. *et al.* Scurvy in hospitalized elderly patients. *J. Nutr. Heal. Aging* **14**, 407–410 (2010).
 128. Ahmed, F. *et al.* Long-term intermittent multiple micronutrient supplementation enhances hemoglobin and micronutrient status more than iron + folic acid supplementation in Bangladeshi rural adolescent girls with nutritional anemia. *J. Nutr.* **140**, 1879–86 (2010).
 129. Hager, D. N. *et al.* The Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) Protocol: A prospective, multi-center, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial. *Trials* **20**, (2019).
 130. Marik, P. E. Vitamin C for the treatment of sepsis: The scientific rationale. *Pharmacol. Ther.* **189**, 63–70 (2018).
 131. Shaik-Dasthagirisahab, Y. B. *et al.* Role of vitamins D, e and C in immunity and inflammation. *J. Biol. Regul. Homeost. Agents* **27**, 291–295 (2013).
 132. Ellulu, M. S., Rahmat, A., Patimah, I., Khaza’Ai, H. & Abed, Y. Effect of vitamin C on inflammation and metabolic markers in hypertensive and/or diabetic obese adults: a randomized controlled trial. *Drug Des. Devel. Ther.* **9**, 3405 (2015).
 133. Mousa, H. A. L. Prevention and Treatment of Influenza, Influenza-Like Illness, and Common Cold by Herbal, Complementary, and Natural Therapies. *J. Evidence-Based*

- Complement. Altern. Med.* **22**, 166–174 (2017).
134. Chen, J. Y. *et al.* Plasma vitamin C is lower in postherpetic neuralgia patients and administration of vitamin C reduces spontaneous pain but not brush-evoked pain. *Clin. J. Pain* **25**, 562–569 (2009).
 135. KLENNER, F. R. The treatment of poliomyelitis and other virus diseases with vitamin C. *South. Med. Surg.* **111**, 209–214 (1949).
 136. Uesato, S. *et al.* Inhibitory effects of 6-O-acylated L-ascorbic acids possessing a straight- or branched-acyl chain on Epstein-Barr virus activation. *Cancer Lett.* **166**, 143–146 (2001).
 137. Cinatl, J. *et al.* In vitro inhibition of human cytomegalovirus replication in human foreskin fibroblasts and endothelial cells by ascorbic acid 2-phosphate. *Antiviral Res.* **27**, 405–418 (1995).
 138. Valero, N. *et al.* Melatonin, minocycline and ascorbic acid reduce oxidative stress and viral titers and increase survival rate in experimental Venezuelan equine encephalitis. *Brain Res.* **1622**, 368–376 (2015).
 139. Harakeh, S., Jariwalla, R. J. & Pauling, L. Suppression of human immunodeficiency virus replication by ascorbate in chronically and acutely infected cells. *Proc. Natl. Acad. Sci. U. S. A.* **87**, 7245–7249 (1990).
 140. Lallement, A., Zandotti, C. & Brouqui, P. Persistent parvovirus B19 viremia with chronic arthralgia treated with ascorbic acid: A case report. *J. Med. Case Rep.* **9**, (2015).
 141. Banic, S. Prevention of rabies by vitamin C. *Nature* **258**, 153–154 (1975).
 142. Bucher, A. & White, N. Vitamin C in the Prevention and Treatment of the Common Cold. *American Journal of Lifestyle Medicine* vol. 10 181–183 (2014).
 143. Hemilä, H. Vitamin C and common cold-induced asthma: A systematic review and statistical analysis. *Allergy, Asthma Clin. Immunol.* **9**, (2013).
 144. Hemilä, H. & Chalker, E. Vitamin C may reduce the duration of mechanical ventilation in critically ill patients: a meta-regression analysis. *J. intensive care* **8**, 15 (2020).
 145. Zhang, M. & Jatava, D. F. Vitamin C supplementation in the

- critically ill: A systematic review and meta-analysis. *SAGE open Med.* **6**, 2050312118807615 (2018).
146. Hemilä, H. & Chalker, E. Vitamin C can shorten the length of stay in the ICU: A meta-analysis. *Nutrients* **11**, (2019).
 147. Kim, G.-N. *et al.* Clinical Features of Herpes Simplex Keratitis in a Korean Tertiary Referral Center: Efficacy of Oral Antiviral and Ascorbic Acid on Recurrence. *Korean J. Ophthalmol.* **32**, 353 (2018).
 148. Hernandez-Patlan, D. *et al.* Comparison of PrestoBlue® and plating method to evaluate antimicrobial activity of ascorbic acid, boric acid and curcumin in an in vitro gastrointestinal model. *J. Appl. Microbiol.* **124**, 423–430 (2018).
 149. Ghosh, T. *et al.* A combination of linalool, vitamin C, and copper synergistically triggers reactive oxygen species and DNA damage and inhibits *Salmonella enterica* subsp. *enterica* serovar typhi and *Vibrio fluvialis*. *Appl. Environ. Microbiol.* **85**, (2019).
 150. Ormerod, M. J. & Unkauf, B. M. Ascorbic Acid (Vitamin C) Treatment of Whooping Cough. *Can. Med. Assoc. J.* **37**, 134–6 (1937).
 151. Puente, V., Demaria, A., Frank, F. M., Batlle, A. & Lombardo, M. E. Anti-parasitic effect of vitamin C alone and in combination with benznidazole against *Trypanosoma cruzi*. *PLoS Negl. Trop. Dis.* **12**, (2018).
 152. Golonka, I. *et al.* Selected Physicochemical and Biological Properties of Ethyl Ascorbic Acid Compared to Ascorbic Acid. *Biol. Pharm. Bull.* **40**, 1199–1206 (2017).
 153. Spittle, C. R. Atherosclerosis and Vitamin C. *Lancet* **298**, 1280–1281 (1971).
 154. Bedard, K. & Krause, K. H. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. *Physiological Reviews* vol. 87 245–313 (2007).
 155. Biesalski, H. K. & McGregor, G. P. Antioxidant therapy in critical care - Is the microcirculation the primary target? in *Critical Care Medicine* vol. 35 (Crit Care Med, 2007).
 156. May, J. M. How does ascorbic acid prevent endothelial dysfunction? *Free Radic. Biol. Med.* **28**, 1421–1429 (2000).
 157. Lassnigg, A. *et al.* Influence of intravenous vitamin E

- supplementation in cardiac surgery on oxidative stress: a double-blinded, randomized, controlled study. *Br. J. Anaesth.* **90**, 148–154 (2003).
158. Carnes, C. A. *et al.* Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. *Circ. Res.* **89**, (2001).
 159. Powers, S. K. & Jackson, M. J. Exercise-induced oxidative stress: Cellular mechanisms and impact on muscle force production. *Physiological Reviews* vol. 88 1243–1276 (2008).
 160. Mullins, A. L. *et al.* Variability in oxidative stress biomarkers following a maximal exercise test. *Biomarkers* **18**, 446–454 (2013).
 161. Strydom, N. B., Kotze, H. F. & Van Der Walt and Rogers, W. H. G. G. Effect of ascorbic acid on rate of heat acclimatization. *J. Appl. Physiol.* **41**, 202–205 (1976).
 162. Zhang, M., Robitaille, L., Eintracht, S. & Hoffer, L. J. Vitamin C provision improves mood in acutely hospitalized patients. *Nutrition* **27**, 530–533 (2011).
 163. Wang, Y. *et al.* Effects of vitamin C and vitamin D administration on mood and distress in acutely hospitalized patients. *Am. J. Clin. Nutr.* **98**, 705–711 (2013).
 164. Shenoy, N., Creagan, E., Witzig, T. & Levine, M. Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly. *Cancer Cell* vol. 34 700–706 (2018).
 165. Monti, D. A. *et al.* Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. *PLoS One* **7**, (2012).
 166. Halabi, I. El *et al.* Ascorbic acid in colon cancer: From the basic to the clinical applications. *International Journal of Molecular Sciences* vol. 19 (2018).
 167. Magrì, A. *et al.* High-dose Vitamin C enhances cancer immunotherapy. *Sci. Transl. Med.* **12**, (2020).
 168. Evans, E. E., Norwood, W. D., Kehoe, R. A. & Machle, W. The effects of ascorbic acid in relation to lead absorption. *J. Am. Med. Assoc.* **121**, 501–504 (1943).
 169. U.S. Department of Health and Human Services and U.S. Department of Agriculture. *2015 - 2020 Dietary Guidelines for*

- Americans*. (Department of Health and Human Services (HHS) and the Department of Agriculture (USDA), 2015). doi:10.1097/NT.0b013e31826c50af.
170. Lykkesfeldt, J., Michels, A. J. & Frei, B. Vitamin C. *Adv. Nutr.* **5**, 16–18 (2014).
 171. Schectman, G., Byrd, J. C. & Gruchow, H. W. The influence of smoking on vitamin C status in adults. *Am. J. Public Health* **79**, 158–162 (1989).
 172. Schectman, G. Estimating ascorbic acid requirements for cigarette smokers. *Ann. N. Y. Acad. Sci.* **686**, 335–336 (1993).
 173. Jacob, R. A. & Sotoudeh, G. Vitamin C function and status in chronic disease. *Nutr. Clin. Care* **5**, 66–74 (2002).
 174. Sollid, L. M. Coeliac disease: Dissecting a complex inflammatory disorder. *Nat. Rev. Immunol.* **2**, 647–655 (2002).
 175. Linaker, B. D. Scurvy and vitamin C deficiency in Crohn's disease. *Postgrad. Med. J.* **55**, 26–29 (1979).
 176. Riordan, H. D. *et al.* A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. *P. R. Health Sci. J.* **24**, 269–276 (2005).
 177. Deicher, R. & Hörl, W. H. Vitamin C in chronic kidney disease and hemodialysis patients. *Kidney Blood Press. Res.* **26**, 100–106 (2003).
 178. Mayland, C. R., Bennett, M. I. & Allan, K. Vitamin C deficiency in cancer patients. *Palliat. Med.* **19**, 17–20 (2005).
 179. Fain, O. *et al.* Hypovitaminosis C in hospitalized patients. *Eur. J. Intern. Med.* **14**, 419–425 (2003).
 180. Evans-Olders, R., Eintracht, S. & Hoffer, L. J. Metabolic origin of hypovitaminosis C in acutely hospitalized patients. *Nutrition* **26**, 1070–4.
 181. Teixeira, A., Carrié, A. S., Généreau, T., Herson, S. & Cherin, P. Vitamin C deficiency in elderly hospitalized patients. *Am. J. Med.* **111**, 502 (2001).
 182. Gan, R., Eintracht, S. & Hoffer, L. J. Vitamin C deficiency in a university teaching hospital. *J. Am. Coll. Nutr.* **27**, 428–33 (2008).
 183. Ravindran, P., Wiltshire, S., Das, K. & Wilson, R. B. Vitamin C deficiency in an Australian cohort of metropolitan surgical patients. *Pathology* **50**, 654–658 (2018).

184. Francescone, M. A. & Levitt, J. Scurvy masquerading as leukocytoclastic vasculitis: a case report and review of the literature. *Cutis* **76**, 261–266 (2005).
185. Stephen, R. & Utecht, T. Scurvy identified in the emergency department: a case report. *J. Emerg. Med.* **21**, 235–237 (2001).
186. Davis, J. L. *et al.* Liposomal-encapsulated Ascorbic Acid: Influence on Vitamin C Bioavailability and Capacity to Protect Against Ischemia-Reperfusion Injury. *Nutr. Metab. Insights* **9**, 25–30 (2016).
187. Hickey, S., Roberts, H. J. & Miller, N. J. Pharmacokinetics of oral vitamin C. *J. Nutr. Environ. Med.* **17**, 169–177 (2008).
188. Valsè Pantellini, G. Breve cenno sulla genesi dei tumori e sopra una eventuale terapia dei medesimi con sali di potassio e in particolare con ascorbato di potassio. *Riv. Patol. Clin.* **25**, 219–225 (1970).
189. Valsè Pantellini, G. Legami idrogeno (H) e salificazione degli stessi da parte del potassio (K) nella strutturazione della materia vivente. *Riv. Patol. Clin.* **29**, 193–198 (1974).
190. Anichini, C. *et al.* Beckwith-Wiedemann syndrome: Potassium ascorbate with ribose therapy in a syndrome with high neoplastic risk. *Anticancer Res.* **31**, 3973–3976 (2011).
191. Anichini, C. *et al.* Antioxidant effects of potassium ascorbate with ribose therapy in a case with Prader Willi Syndrome. *Dis. Markers* **33**, 179–183 (2012).
192. Anichini, C. *et al.* Antioxidant effects of potassium ascorbate with ribose in costello syndrome. *Anticancer Res.* **33**, 691–696 (2013).
193. Anichini, C. *et al.* Antioxidant strategies in genetic syndromes with high neoplastic risk in infant age. *Tumori* **100**, 590–599 (2014).
194. Cavicchio, C. *et al.* Potassium Ascorbate with Ribose: Promising Therapeutic Approach for Melanoma Treatment. *Oxid. Med. Cell. Longev.* **2017**, (2017).
195. Paoli, G. The biomagnetic nature of cancer and the role of potassium ascorbate and ribose against cellular degeneration. *J. New Energy* **7**, 114–119 (2003).
196. Paoli, G. *Ascorbato di potassio*. (Terra Nuova Edizioni, 2020).
197. Bruni, L., Babarinde, A. A., Ortalli, I. & Croci, S. K-D: Rib

- dampens Hs 578T cancer cell chemoinvasion and proliferation. *Cancer Cell Int.* **14**, (2014).
198. Croci, S., Bruni, L., Bussolati, S., Castaldo, M. & Dondi, M. Potassium bicarbonate and D-ribose effects on A72 canine and HTB-126 human cancer cell line proliferation in vitro. *Cancer Cell Int.* **11**, (2011).
 199. Hemilä, H. Vitamin C may alleviate exercise-induced bronchoconstriction: A meta-analysis. *BMJ Open* **3**, (2013).
 200. Douglas, R. M., Hemilä, H., Chalker, E. & Treacy, B. Vitamin C for preventing and treating the common cold. *Cochrane database Syst. Rev.* CD000980 (2007) doi:10.1002/1465-1858.CD000980.pub3 PM - 17636648 M4 - Citavi.
 201. Hemilä, H. The role of vitamin C in the treatment of the common cold. *Am. Fam. Physician* **76**, 1111,1115 (2007).
 202. Johnston, C. S. The antihistamine action of ascorbic acid. *Subcell. Biochem.* **25**, 189–213 (1996).
 203. Li, Y. & Schellhorn, H. E. New developments and novel therapeutic perspectives for vitamin C. *J. Nutr.* **137**, 2171–2184 (2007).
 204. Ye, Z. & Song, H. Antioxidant vitamins intake and the risk of coronary heart disease: meta-analysis of cohort studies. *Eur. J. Cardiovasc. Prev. Rehabil.* **15**, 26–34 (2008).
 205. Willcox, B. J., Curb, J. D. & Rodriguez, B. L. Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies. *Am. J. Cardiol.* **101**, 75D-86D (2008).
 206. Carr, A. C. & Frei, B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. *Am. J. Clin. Nutr.* **69**, 1086–1107 (1999).
 207. Honarbakhsh, S. & Schachter, M. Vitamins and cardiovascular disease. *Br. J. Nutr.* **101**, 1113–1131 (2009).
 208. Osganian, S. K. *et al.* Vitamin C and risk of coronary heart disease in women. *J. Am. Coll. Cardiol.* **42**, 246–252 (2003).
 209. Myint, P. K. *et al.* Plasma vitamin C concentrations predict risk of incident stroke over 10 y in 20 649 participants of the European Prospective Investigation into Cancer Norfolk prospective population study. *Am. J. Clin. Nutr.* **87**, 64–69 (2008).
 210. Knekt, P. *et al.* Antioxidant vitamins and coronary heart disease

- risk: a pooled analysis of 9 cohorts. *Am. J. Clin. Nutr.* **80**, 1508–1520 (2004).
211. Cook, N. R. *et al.* A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. *Arch. Intern. Med.* **167**, 1610–1618 (2007).
 212. Sesso, H. D. *et al.* Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. *JAMA* **300**, 2123–2133 (2008).
 213. Hercberg, S. *et al.* The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. *Arch. Intern. Med.* **164**, 2335–2342 (2004).
 214. Bleys, J., Miller, E. R., Pastor-Barriuso, R., Appel, L. J. & Guallar, E. Vitamin-mineral supplementation and the progression of atherosclerosis: a meta-analysis of randomized controlled trials. *Am. J. Clin. Nutr.* **84**, 880–885 (2006).
 215. Shekelle, P., Morton, S. & Hardy, M. L. Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease. *Evid. Rep. Technol. Assess. (Summ.)* 1–3 (2003).
 216. Qiao, Y.-L. *et al.* Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial. *J. Natl. Cancer Inst.* **101**, 507–518 (2009).
 217. van Leeuwen, R. *et al.* Dietary intake of antioxidants and risk of age-related macular degeneration. *JAMA* **294**, 3101–3107 (2005).
 218. Evans, J. Primary prevention of age related macular degeneration. *BMJ* **335**, 729 (2007).
 219. Evans, J. R. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. *Cochrane database Syst. Rev.* CD000254 (2006) doi:10.1002/14651858.CD000254.pub2 PM - 16625532.
 220. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS

- report no. 8. *Arch. Ophthalmol. (Chicago, Ill. 1960)* **119**, 1417–1436 (2001).
221. Chew, E. Y. *et al.* Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: The Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. *JAMA - J. Am. Med. Assoc.* **309**, 2005–2015 (2013).
222. Yoshida, M. *et al.* Prospective study showing that dietary vitamin C reduced the risk of age-related cataracts in a middle-aged Japanese population. *Eur. J. Nutr.* **46**, 118–124 (2007).
223. Rautiainen, S., Lindblad, B. E., Morgenstern, R. & Wolk, A. Vitamin C supplements and the risk of age-related cataract: a population-based prospective cohort study in women. *Am. J. Clin. Nutr.* **91**, 487–493 (2010).
224. Sperduto, R. D. *et al.* The Linxian cataract studies. Two nutrition intervention trials. *Arch. Ophthalmol. (Chicago, Ill. 1960)* **111**, 1246–1253 (1993).
225. Mousavi, S., Bereswill, S. & Heimesaat, M. M. Immunomodulatory and antimicrobial effects of vitamin C. *Eur. J. Microbiol. Immunol.* **9**, 73–79 (2019).
226. Maggini, S., Beveridge, S. & Suter, M. A combination of high-dose vitamin C plus zinc for the common cold. *J. Int. Med. Res.* **40**, 28–42 (2012).
227. Hemilä, H. Vitamin C supplementation and common cold symptoms: Factors affecting the magnitude of the benefit. *Med. Hypotheses* **52**, 171–178 (1999).
228. Hemilä, H. The effect of vitamin C on bronchoconstriction and respiratory symptoms caused by exercise: A review and statistical analysis. *Allergy, Asthma and Clinical Immunology* vol. 10 58 (2014).
229. Vollbracht, C., Raithel, M., Krick, B., Kraft, K. & Hagel, A. F. Intravenous vitamin C in the treatment of allergies: an interim subgroup analysis of a long-term observational study. *J. Int. Med. Res.* **46**, 3640–3655 (2018).
230. Yuan, X. *et al.* Effects of vitamin C supplementation on blood pressure and hypertension control in response to ambient temperature changes in patients with essential hypertension. *Clin. Exp. Hypertens.* **41**, 414–421 (2019).
231. Juraschek, S. P., Guallar, E., Appel, L. J. & Miller, E. R. Effects

- of vitamin c supplementation on blood pressure: A meta-analysis of randomized controlled trials. *Am. J. Clin. Nutr.* **95**, 1079–1088 (2012).
232. Chambial, S., Dwivedi, S., Shukla, K. K., John, P. J. & Sharma, P. Vitamin C in disease prevention and cure: An overview. *Indian Journal of Clinical Biochemistry* vol. 28 314–328 (2013).
233. Ashor, A. W. *et al.* Effect of vitamin C and vitamin e supplementation on endothelial function: A systematic review and meta-analysis of randomised controlled trials. *Br. J. Nutr.* **113**, 1182–1194 (2015).
234. Lee, D. M., Hoffman, W. H., Carl, G. F., Khichi, M. & Cornwell, P. E. Lipid peroxidation and antioxidant vitamins prior to, during, and after correction of diabetic ketoacidosis. *J. Diabetes Complications* **16**, 294–300 (2002).
235. Dalton, R. R., Hoffman, W. H., Passmore, G. G. & Martin, S. L. A. Plasma C-Reactive Protein Levels in Severe Diabetic Ketoacidosis. *Ann. Clin. Lab. Sci.* **33**, 435–442 (2003).
236. Ramos, C. *et al.* Effects of a novel ascorbate-based protocol on infarct size and ventricle function in acute myocardial infarction patients undergoing percutaneous coronary angioplasty. *Arch. Med. Sci.* **13**, 558–567 (2017).
237. Shi, R. *et al.* Sole and combined vitamin C supplementation can prevent postoperative atrial fibrillation after cardiac surgery: A systematic review and meta-analysis of randomized controlled trials. *Clinical Cardiology* vol. 41 871–878 (2018).
238. Xu, Y., Zheng, X., Liang, B., Gao, J. & Gu, Z. Vitamins for Prevention of Contrast-induced Acute Kidney Injury: A Systematic Review and Trial Sequential Analysis. *Am. J. Cardiovasc. Drugs* **18**, 373–386 (2018).
239. Sadat, U., Usman, A., Gillard, J. H. & Boyle, J. R. Does ascorbic acid protect against contrast-induced acute kidney injury in patients undergoing coronary angiography: A systematic review with meta-analysis of randomized, controlled trials. *J. Am. Coll. Cardiol.* **62**, 2167–2175 (2013).
240. Ashor, A. W. *et al.* Effects of Vitamin C supplementation on glycaemic control: A systematic review and meta-analysis of randomised controlled trials. *Eur. J. Clin. Nutr.* **71**, 1371–1380

- (2017).
241. Verma, A. & Kanwar, K. C. Human sperm motility and lipid peroxidation in different ascorbic acid concentrations: an in vitro analysis. *Andrologia* **30**, 325–329 (1998).
 242. Shibuya, N., Humphers, J. M., Agarwal, M. R. & Jupiter, D. C. Efficacy and Safety of High-dose Vitamin C on Complex Regional Pain Syndrome in Extremity Trauma and Surgery-Systematic Review and Meta-Analysis. *J. Foot Ankle Surg.* **52**, 62–66 (2013).
 243. Xia, J. *et al.* Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid. *EBioMedicine* **18**, 41–49 (2017).
 244. Covarrubias-Pinto, A., Acuña, A. I., Beltrán, F. A., Torres-Díaz, L. & Castro, M. A. Old things new view: Ascorbic acid protects the brain in neurodegenerative disorders. *International Journal of Molecular Sciences* vol. 16 28194–28217 (2015).
 245. Travica, N. *et al.* Vitamin c status and cognitive function: A systematic review. *Nutrients* **9**, 1–21 (2017).
 246. Kocot, J., Luchowska-Kocot, D., Kiełczykowska, M., Musik, I. & Kurzepa, J. Does vitamin c influence neurodegenerative diseases and psychiatric disorders? *Nutrients* vol. 9 (2017).
 247. Delgado, P. L. Depression: The case for a monoamine deficiency. *J. Clin. Psychiatry* **61**, 7–11 (2000).
 248. Hornig, D. Distribution of ascorbic acid, metabolites and analogues in man and animals. *Ann. N. Y. Acad. Sci.* **258**, 103–118 (1975).
 249. Hughes, R. E., Hurley, R. J. & Jones, P. R. The retention of ascorbic acid by guinea-pig tissues. *Br. J. Nutr.* **26**, 433–438 (1971).
 250. Vissers, M. C. M., Bozonet, S. M., Pearson, J. F. & Braithwaite, L. J. Dietary ascorbate intake affects steady state tissue concentrations in vitamin C-deficient mice: Tissue deficiency after suboptimal intake and superior bioavailability from a food source (kiwifruit). *Am. J. Clin. Nutr.* **93**, 292–301 (2011).
 251. Pauling, L. *How to live longer and feel better*. (Oregon State University Press, 2006).
 252. Tanaka, H. *et al.* Reduction of resuscitation fluid volumes in severely burned patients using ascorbic acid administration: A

- randomized, prospective study. *Arch. Surg.* **135**, 326–331 (2000).
253. Kahn, S. A., Beers, R. J. & Lentz, C. W. Resuscitation after severe burn injury using high-dose ascorbic acid: A retrospective review. *J. Burn Care Res.* **32**, 110–117 (2011).
254. Castro, S. M. *et al.* Antioxidant treatment ameliorates respiratory syncytial virus-induced disease and lung inflammation. *Am. J. Respir. Crit. Care Med.* **174**, 1361–1369 (2006).
255. Fowler, A. A. *et al.* Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients with Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. in *JAMA - Journal of the American Medical Association* vol. 322 1261–1270 (American Medical Association, 2019).
256. Kim, W.-Y. *et al.* Combined vitamin C, hydrocortisone, and thiamine therapy for patients with severe pneumonia who were admitted to the intensive care unit: Propensity score-based analysis of a before-after cohort study. *J. Crit. Care* **47**, 211–218 (2018).
257. Waqas Khan, H. M., Parikh, N., Megala, S. M. & Predeteanu, G. S. Unusual Early Recovery of a Critical COVID-19 Patient After Administration of Intravenous Vitamin C. *Am. J. Case Rep.* **21**, e925521 (2020).
258. Fowler, A. A. *et al.* Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. *J. Transl. Med.* **12**, 32 (2014).
259. Hemilä, H. & Chalker, E. Vitamin C may reduce the duration of mechanical ventilation in critically ill patients: A meta-regression analysis. *J. Intensive Care* **8**, (2020).
260. Cheng, R. Z. Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)? *Med. drug Discov.* **5**, 100028 (2020).
261. Matthay, M. A., Aldrich, J. M. & Gotts, J. E. Treatment for severe acute respiratory distress syndrome from COVID-19. *Lancet. Respir. Med.* **8**, 433–434 (2020).
262. Hernández, A. *et al.* Dos terapias conocidas podrían ser efectivas como adyuvantes en el paciente crítico infectado por

- COVID-19. *Rev. Esp. Anesthesiol. Reanim.* **67**, 245–252 (2020).
263. Frommelt, M. A., Kory, P. & Long, M. T. Letter on Update to the Vitamin C, Thiamine, and Steroids in Sepsis (VICTAS) Protocol. *Trials* **21**, 350 (2020).
264. Kamen, J. A Long-Standing Physician Bias is Contributing to COVID-19 Death Rates. *Medium* (2020).
265. Ngo, B., Van Riper, J. M., Cantley, L. C. & Yun, J. Targeting cancer vulnerabilities with high-dose vitamin C. *Nat. Rev. Cancer* **19**, 271–282 (2019).
266. Cameron, E. & Pauling, L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. *Proc. Natl. Acad. Sci. U. S. A.* **73**, 3685–3689 (1976).
267. Cameron, E. & Pauling, L. Supplemental ascorbate in the supportive treatment of cancer: Reevaluation of prolongation of survival times in terminal human cancer. *Proc. Natl. Acad. Sci. U. S. A.* **75**, 4538–4542 (1978).
268. Creagan, E. T. *et al.* Failure of High-Dose Vitamin C (Ascorbic Acid) Therapy to Benefit Patients with Advanced Cancer: A Controlled Trial. *N. Engl. J. Med.* **301**, 687–690 (1979).
269. Moertel, C. G. *et al.* High-Dose Vitamin C versus Placebo in the Treatment of Patients with Advanced Cancer Who Have Had No Prior Chemotherapy: A Randomized Double-Blind Comparison. *N. Engl. J. Med.* **312**, 137–141 (1985).
270. Bruno, E. J., Ziegenfuss, T. N. & Landis, J. Vitamin C: research update. *Curr. Sports Med. Rep.* **5**, 177–181 (2006).
271. Levine, M. *et al.* Ideal vitamin C intake. *BioFactors* **15**, 71–74 (2001).
272. Corpe, C. P., Eck, P., Wang, J., Al-Hasani, H. & Levine, M. Intestinal dehydroascorbic acid (DHA) transport mediated by the facilitative sugar transporters, GLUT2 and GLUT8. *J. Biol. Chem.* **288**, 9092–9101 (2013).
273. Sotiriou, S. *et al.* Ascorbic-acid transporter Slc23a1 is essential for vitamin C transport into the brain and for perinatal survival. *Nat. Med.* **8**, 514–517 (2002).
274. Padayatty, S. J. *et al.* Intravenously administered vitamin C as cancer therapy: three cases. *CMAJ* **174**, 937–942 (2006).
275. Park, C. H. *et al.* Depletion of l-ascorbic acid alternating with

- its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromes. *Eur. J. Haematol.* **83**, 108–118 (2009).
276. Hoffer, L. J. *et al.* Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. *Ann. Oncol.* **19**, 1969–1974 (2008).
 277. Chen, Q. *et al.* Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 11105–11109 (2008).
 278. Levine, M., Espey, M. G. & Chen, Q. Losing and finding a way at C: new promise for pharmacologic ascorbate in cancer treatment. *Free Radic. Biol. Med.* **47**, 27–29 (2009).
 279. Cross, C. E. *et al.* Oxygen radicals and human disease. Davis conference. *Ann. Intern. Med.* **107**, 526–545 (1987).
 280. Andersen, J. K. Oxidative stress in neurodegeneration: Cause or consequence? *Nat. Rev. Neurosci.* **10**, 25 (2004).
 281. Mügge, A. The role of reactive oxygen species in atherosclerosis. *Z. Kardiol.* **87**, 851–864 (1998).
 282. Paravicini, T. M. & Touyz, R. M. Redox signaling in hypertension. *Cardiovasc. Res.* **71**, 247–258 (2006).
 283. Haigis, M. C. & Yankner, B. A. The Aging Stress Response. *Molecular Cell* vol. 40 333–344 (2010).
 284. Schieber, M. & Chandel, N. S. ROS function in redox signaling and oxidative stress. *Current Biology* vol. 24 (2014).
 285. Chio, I. I. C. & Tuveson, D. A. ROS in Cancer: The Burning Question. *Trends Mol. Med.* **23**, 411–429 (2017).
 286. Irani, K. *et al.* Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. *Science (80-)*. **275**, 1649–1652 (1997).
 287. Ogrunc, M. *et al.* Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation. *Cell Death Differ.* **21**, 998–1012 (2014).
 288. Sohn, J. & Rudolph, J. Catalytic and chemical competence of regulation of Cdc25 phosphatase by oxidation/reduction. *Biochemistry* **42**, 10060–10070 (2003).
 289. Shibutani, S., Takeshita, M. & Grollman, A. P. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. *Nature* **349**, 431–434 (1991).

290. Sayin, V. I. *et al.* Cancer: Antioxidants accelerate lung cancer progression in mice. *Sci. Transl. Med.* **6**, (2014).
291. Piskounova, E. *et al.* Oxidative stress inhibits distant metastasis by human melanoma cells. *Nature* **527**, 186–191 (2015).
292. Gal, K. Le *et al.* Antioxidants can increase melanoma metastasis in mice. *Sci. Transl. Med.* **7**, (2015).
293. Klein, E. A. *et al.* Vitamin E and the risk of prostate cancer: The selenium and vitamin E cancer prevention trial (SELECT). *JAMA - J. Am. Med. Assoc.* **306**, 1549–1556 (2011).
294. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. The effect of vitamin e and beta carotene on the incidence of lung cancer and other cancers in male smokers. *N. Engl. J. Med.* **330**, 1029–1035 (1994).
295. Omenn, G. S. *et al.* Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. *N. Engl. J. Med.* **334**, 1150–1155 (1996).
296. Wondrak, G. T. Redox-directed cancer therapeutics: Molecular mechanisms and opportunities. *Antioxidants and Redox Signaling* vol. 11 3013–3069 (2009).
297. Rawal, M. *et al.* Manganoporphyrins increase ascorbate-induced cytotoxicity by enhancing H₂O₂ generation. *Cancer Res.* **73**, 5232–5241 (2013).
298. Duarte, T. L., Almeida, G. M. & Jones, G. D. D. Investigation of the role of extracellular H₂O₂ and transition metal ions in the genotoxic action of ascorbic acid in cell culture models. *Toxicol. Lett.* **170**, 57–65 (2007).
299. Sakagami, H., Satoh, K., Fukuchi, K., Gomi, K. & Takeda, M. Effect of an iron-chelator on ascorbate-induced cytotoxicity. *Free Radic. Biol. Med.* **23**, 260–270 (1997).
300. Buettner, G. R. & Jurkiewicz, B. A. Catalytic Metals, Ascorbate and Free Radicals: Combinations to Avoid. *Radiat. Res.* **145**, 532 (1996).
301. Clément, M. V., Ramalingam, J., Long, L. H. & Halliwell, B. The in vitro cytotoxicity of ascorbate depends on the culture medium used to perform the assay and involves hydrogen peroxide. *Antioxidants Redox Signal.* **3**, 157–163 (2001).
302. Hentze, M. W., Muckenthaler, M. U., Galy, B. & Camaschella, C. Two to Tango: Regulation of Mammalian Iron Metabolism.

- Cell* vol. 142 24–38 (2010).
303. Torti, S. V. & Torti, F. M. Iron and cancer: More ore to be mined. *Nat. Rev. Cancer* **13**, 342–355 (2013).
 304. Manz, D. H., Blanchette, N. L., Paul, B. T., Torti, F. M. & Torti, S. V. Iron and cancer: Recent insights. *Ann. N. Y. Acad. Sci.* **1368**, 149–161 (2016).
 305. Ma, E. *et al.* Pharmacologic ascorbate induces neuroblastoma cell death by hydrogen peroxide mediated DNA damage and reduction in cancer cell glycolysis. *Free Radic. Biol. Med.* **113**, 36–47 (2017).
 306. Pinnix, Z. K. *et al.* Ferroportin and iron regulation in breast cancer progression and prognosis. *Sci. Transl. Med.* **2**, (2010).
 307. Panis, C. *et al.* Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer. *Breast Cancer Res. Treat.* **133**, 881–888 (2012).
 308. Verrax, J. & Calderon, P. B. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. *Free Radic. Biol. Med.* **47**, 32–40 (2009).
 309. Yun, J. *et al.* Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. *Science* (80-.). **350**, 1391–1396 (2015).
 310. May, J. M., Qu, Z. C., Whitesell, R. R. & Cobb, C. E. Ascorbate recycling in human erythrocytes: Role of GSH in reducing dehydroascorbate. *Free Radic. Biol. Med.* **20**, 543–551 (1996).
 311. Tu, H., Wang, Y., Li, H., Brinster, L. R. & Levine, M. Chemical Transport Knockout for Oxidized Vitamin C, Dehydroascorbic Acid, Reveals Its Functions in vivo. *EBioMedicine* **23**, 125–135 (2017).
 312. Quinn, J. *et al.* Effect of High-Dose Vitamin C Infusion in a Glucose-6-Phosphate Dehydrogenase-Deficient Patient. *Case Rep. Med.* **2017**, (2017).
 313. Szatrowski, T. P. & Nathan, C. F. Production of Large Amounts of Hydrogen Peroxide by Human Tumor Cells. *Cancer Res.* **51**, 794–798 (1991).
 314. Policastro, L. L., Ibañez, I. L., Notcovich, C., Duran, H. A. & Podhajcer, O. L. The tumor microenvironment: Characterization, redox considerations, and novel approaches

- for reactive oxygen species-targeted gene therapy. *Antioxidants Redox Signal.* **19**, 854–895 (2013).
315. Semenza, G. L. Targeting HIF-1 for cancer therapy. *Nat. Rev. Cancer* **3**, 721–732 (2003).
 316. Semenza, G. L. Oxygen sensing, homeostasis, and disease. *N. Engl. J. Med.* **365**, 537–547 (2011).
 317. Kuiper, C., Dachs, G. U., Currie, M. J. & Vissers, M. C. M. Intracellular ascorbate enhances hypoxia-inducible factor (HIF)-hydroxylase activity and preferentially suppresses the HIF-1 transcriptional response. *Free Radic. Biol. Med.* **69**, 308–317 (2014).
 318. Vissers, M. C. M. & Das, A. B. Potential mechanisms of action for vitamin C in cancer: Reviewing the evidence. *Front. Physiol.* **9**, 809 (2018).
 319. Wilkes, J. G. *et al.* Pharmacologic ascorbate (P-AscH⁻) suppresses hypoxia-inducible Factor-1 α (HIF-1 α) in pancreatic adenocarcinoma. *Clin. Exp. Metastasis* **35**, 37–51 (2018).
 320. Gao, P. *et al.* HIF-Dependent Antitumorigenic Effect of Antioxidants In Vivo. *Cancer Cell* **12**, 230–238 (2007).
 321. Shenoy, N. *et al.* Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells. *Blood Cancer J.* **7**, e587 (2017).
 322. Yin, R. *et al.* Ascorbic acid enhances tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. *J. Am. Chem. Soc.* **135**, 10396–10403 (2013).
 323. Cimmino, L. *et al.* Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression. *Cell* **170**, 1079-1095.e20 (2017).
 324. Mingay, M. *et al.* Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia. *Leukemia* **32**, 11–20 (2018).
 325. Peng, D. *et al.* Vitamin C increases 5-hydroxymethylcytosine level and inhibits the growth of bladder cancer. *Clin. Epigenetics* **10**, (2018).
 326. Wohlrab, C., Phillips, E. & Dachs, G. U. Vitamin c transporters in cancer: Current understanding and gaps in knowledge. *Frontiers in Oncology* vol. 7 (2017).
 327. Kuiper, C., Vissers, M. C. M. & Hicks, K. O. Pharmacokinetic

- modeling of ascorbate diffusion through normal and tumor tissue. *Free Radic. Biol. Med.* **77**, 340–352 (2014).
328. Welsh, J. L. *et al.* Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): Results from a phase i clinical trial. *Cancer Chemother. Pharmacol.* **71**, 765–775 (2013).
329. Padayatty, S. J. *et al.* Vitamin C: Intravenous use by complementary and alternative medicine practitioners and adverse effects. *PLoS One* **5**, (2010).
330. Hecht, S. S. Approaches to cancer prevention based on an understanding of N-nitrosamine carcinogenesis. *Proc. Soc. Exp. Biol. Med.* **216**, 181–191 (1997).
331. Zhang, S. *et al.* Dietary carotenoids and vitamins A, C, and E and risk of breast cancer. *J. Natl. Cancer Inst.* **91**, 547–556 (1999).
332. Galan, P. *et al.* Antioxidant status and risk of cancer in the SU.VI.MAX study: is the effect of supplementation dependent on baseline levels? *Br. J. Nutr.* **94**, 125–132 (2005).
333. Gaziano, J. M. *et al.* Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. *JAMA* **301**, 52–62 (2009).
334. Lin, J. *et al.* Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial. *J. Natl. Cancer Inst.* **101**, 14–23 (2009).
335. Taylor, P. R. *et al.* Prevention of esophageal cancer: the nutrition intervention trials in Linxian, China. Linxian Nutrition Intervention Trials Study Group. *Cancer Res.* **54**, 2029s-2031s (1994).
336. Campbell, E. J. *et al.* Restoring physiological levels of ascorbate slows tumor growth and moderates HIF-1 pathway activity in Gulo^{-/-} mice. *Cancer Med.* **4**, 303–314 (2015).
337. Campbell, E. J. *et al.* Pharmacokinetic and anti-cancer properties of high dose ascorbate in solid tumours of ascorbate-dependent mice. *Free Radic. Biol. Med.* **99**, 451–462 (2016).
338. Cha, J. *et al.* Ascorbate supplementation inhibits growth and metastasis of B16FO melanoma and 4T1 breast cancer cells in vitamin C-deficient mice. *Int. J. Oncol.* **42**, 55–64 (2013).
339. Anthony, H. M. & Schorah, C. J. Severe hypovitaminosis c in

- lung-cancer patients: The utilization of vitamin c in surgical repair and lymphocyte-related host resistance. *Br. J. Cancer* **46**, 354–367 (1982).
340. F. Ullah, M. *et al.* Ascorbic Acid in Cancer Chemoprevention: Translational Perspectives and Efficacy. *Curr. Drug Targets* **13**, 1757–1771 (2012).
341. Ki, W. L., Hyong, J. L., Surh, Y. J. & Chang, Y. L. Vitamin C and cancer chemoprevention: Reappraisal. *Am. J. Clin. Nutr.* **78**, 1074–1078 (2003).
342. Khaw, K. T. *et al.* Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: A prospective population study. *Lancet* **357**, 657–663 (2001).
343. Luo, J., Shen, L. & Zheng, D. Association between vitamin C intake and lung cancer: A dose-response meta-analysis. *Sci. Rep.* **4**, (2014).
344. Harris, H. R., Orsini, N. & Wolk, A. Vitamin C and survival among women with breast cancer: A Meta-analysis. *Eur. J. Cancer* **50**, 1223–1231 (2014).
345. Harris, H. R., Bergkvist, L. & Wolk, A. Vitamin C intake and breast cancer mortality in a cohort of Swedish women. *Br. J. Cancer* **109**, 257–264 (2013).
346. Agathocleous, M. *et al.* Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. *Nature* **549**, 476–481 (2017).
347. Michels, A. J., Hagen, T. M. & Frei, B. Human Genetic Variation Influences Vitamin C Homeostasis by Altering Vitamin C Transport and Antioxidant Enzyme Function. *Annu. Rev. Nutr.* **33**, 45–70 (2013).
348. Rouleau, L. *et al.* Synergistic effects of ascorbate and sorafenib in hepatocellular carcinoma: New insights into ascorbate cytotoxicity. *Free Radic. Biol. Med.* **95**, 308–322 (2016).
349. Serrano, O. K. *et al.* Antitumor effect of pharmacologic ascorbate in the B16 murine melanoma model. *Free Radic. Biol. Med.* **87**, 193–203 (2015).
350. Huijskens, M. J. A. J., Wodzig, W. K. W. H., Walczak, M., Germeraad, W. T. V. & Bos, G. M. J. Ascorbic acid serum levels are reduced in patients with hematological malignancies.

- Results Immunol.* **6**, 8–10 (2016).
351. Liu, M. *et al.* Vitamin C increases viral mimicry induced by 5-aza-2'-deoxycytidine. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 10238–10244 (2016).
 352. Chapman, J., Hunter, V. J. & Drisko, J. A. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. *J. Am. Coll. Nutr.* **22**, 118–123 (2003).
 353. Seifried, H. E., Anderson, D. E., Sorkin, B. C. & Costello, R. B. Free radicals: the pros and cons of antioxidants. Executive summary report. *J. Nutr.* **134**, 3143S–3163S (2004).
 354. Lawenda, B. D. *et al.* Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? *J. Natl. Cancer Inst.* **100**, 773–783 (2008).
 355. Ladas, E. J. *et al.* Antioxidants and cancer therapy: a systematic review. *J. Clin. Oncol.* **22**, 517–528 (2004).
 356. Agus, D. B., Vera, J. C. & Golde, D. W. Stromal cell oxidation: A mechanism by which tumors obtain vitamin C. *Cancer Res.* **59**, 4555–4558 (1999).
 357. Nauman, G., Gray, J. C., Parkinson, R., Levine, M. & Paller, C. J. Systematic review of intravenous ascorbate in cancer clinical trials. *Antioxidants* vol. 7 (2018).
 358. Kuiper, C. & Vissers, M. C. M. Ascorbate as a cofactor for Fe- and 2-oxoglutarate dependent dioxygenases: Physiological activity in tumour growth and progression. *Frontiers in Oncology* vol. 4 359 (2014).
 359. Schoenfeld, J. D. *et al.* O₂⁻ and H₂O₂-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. *Cancer Cell* **31**, 487–500.e8 (2017).
 360. Mustafi, S. *et al.* Vitamin C sensitizes melanoma to BET inhibitors. *Cancer Res.* **78**, 572–583 (2018).
 361. Du, J. *et al.* Pharmacological ascorbate radiosensitizes pancreatic cancer. *Cancer Res.* **75**, 3314–3326 (2015).
 362. Herst, P. M., Broadley, K. W. R., Harper, J. L. & McConnell, M. J. Pharmacological concentrations of ascorbate radiosensitize glioblastoma multiforme primary cells by increasing oxidative DNA damage and inhibiting G2/M arrest. *Free Radic. Biol. Med.* **52**, 1486–1493 (2012).

363. Espey, M. G. *et al.* Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. *Free Radic. Biol. Med.* **50**, 1610–1619 (2011).
364. Shim, E. H. *et al.* L-2-hydroxyglutarate: An epigenetic modifier and putative oncometabolite in renal cancer. *Cancer Discov.* **4**, 1290–1298 (2014).
365. Hoffer, L. J. *et al.* High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: A phase I-II clinical trial. *PLoS One* **10**, (2015).
366. Heaney, M. L. *et al.* Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. *Cancer Res.* **68**, 8031–8038 (2008).
367. Prasad, K. N. Rationale for using high-dose multiple dietary antioxidants as an adjunct to radiation therapy and chemotherapy. *J. Nutr.* **134**, 3182S–3S (2004).
368. Vollbracht, C. *et al.* Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: Results of a retrospective, multicentre, epidemiological cohort study in Germany. *In Vivo (Brooklyn)*. **25**, 983–990 (2011).
369. Zhao, H. *et al.* The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. *Leuk. Res.* **66**, 1–7 (2018).
370. Hathcock, J. N. Vitamins and minerals: efficacy and safety. *Am. J. Clin. Nutr.* **66**, 427–437 (1997).
371. Taylor, E. N., Stampfer, M. J. & Curhan, G. C. Dietary factors and the risk of incident kidney stones in men: New insights after 14 years of follow-up. *J. Am. Soc. Nephrol.* **15**, 3225–3232 (2004).
372. Jiang, K. *et al.* Ascorbic Acid Supplements and Kidney Stones Incidence Among Men and Women: A systematic review and meta-analysis. *Urol. J.* **16**, 115–120 (2019).
373. Auer, B. L., Auer, D. & Rodgers, A. L. Relative hyperoxaluria, crystalluria and haematuria after megadose ingestion of vitamin C. *Eur. J. Clin. Invest.* **28**, 695–700 (1998).
374. Auer, B. L., Auer, D. & Rodgers, A. L. The effect of ascorbic acid ingestion on the biochemical and physicochemical risk

- factors associated with calcium oxalate kidney stone formation. *Clin. Chem. Lab. Med.* **36**, 143–147 (1998).
375. NIH. Vitamin C - Health Professional Fact Sheet. <https://ods.od.nih.gov/factsheets/VitaminC-HealthProfessional/> (2020).
376. Freyer, A. M. Drugs in Pregnancy and Lactation 8th Edition: A Reference Guide to Fetal and Neonatal Risk. *Obstet. Med.* **2**, 89–89 (2009).
377. Briggs, G., Freeman, R. & Yaffe, S. *Drugs in Pregnancy and Lactation*. (Lippincott Williams & Wilkins, 2002).
378. Romeu-Nadal, M., Castellote, A. I. & López-Sabater, M. C. Effect of cold storage on vitamins C and E and fatty acids in human milk. *Food Chem.* **106**, 65–70 (2008).
379. Bromley, J., Hughes, B. G. M., Leong, D. C. S. & Buckley, N. A. Life-threatening interaction between complementary medicines: cyanide toxicity following ingestion of amygdalin and vitamin C. *Ann. Pharmacother.* **39**, 1566–9 (2005).
380. Perrone, G. *et al.* Ascorbic acid inhibits antitumor activity of bortezomib in vivo. *Leukemia* **23**, 1679–1686 (2009).
381. Gonzalez, J. P. *et al.* Influence of vitamin C on the absorption and first pass metabolism of propranolol. *Eur. J. Clin. Pharmacol.* **48**, 295–7 (1995).
382. Cheung, M. C., Zhao, X. Q., Chait, A., Albers, J. J. & Brown, B. G. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. *Arterioscler. Thromb. Vasc. Biol.* **21**, 1320–1326 (2001).
383. Brown, B. G. *et al.* Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *N. Engl. J. Med.* **345**, 1583–1592 (2001).
384. Feetam, C. L., Leach, R. H. & Meynell, M. J. Lack of a clinically important interaction between warfarin and ascorbic acid. *Toxicol. Appl. Pharmacol.* **31**, 544–7 (1975).
385. Centonze Quinto D Carelli S Di Paolo E Montemurno L Gesualdo, D. M. *Interferenze nella determinazione della glicemia effettuata con i glucometri elettrochimici nel paziente ospedalizzato.*
386. Rees, D. C., Kelsey, H. & Richards, J. D. M. Acute haemolysis

- induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. *Br. Med. J.* **306**, 841–842 (1993).
387. Marik, P. E. Is intravenous vitamin C contraindicated in patients with G6PD deficiency? *Critical Care* vol. 23 (2019).
388. Barton, J. C. *et al.* Management of hemochromatosis. *Ann. Intern. Med.* **129**, 932–939 (1998).
389. Rivers, J. M. Safety of high-level vitamin C ingestion. *Int. J. Vitam. Nutr. Res. Suppl.* **30**, 95–102 (1989).
390. Campbell, A. & Jack, T. Acute Reactions to Mega Ascorbic Acid Therapy in Malignant Disease. *Scott. Med. J.* **24**, 151–153 (1979).
391. Hemilä, H. & Kaprio, J. Subgroup analysis of large trials can guide further research: A case study of vitamin E and pneumonia. *Clin. Epidemiol.* **3**, 51–59 (2011).
392. Hemilä, H. Vitamin E and the risk of pneumonia: Using the *i* 2 statistic to quantify heterogeneity within a controlled trial. *Br. J. Nutr.* **116**, 1530–1536 (2016).
393. Hemilä, H., Kaprio, J., Virtamo, J. & Albanes, D. The Effect of Vitamin E on Common Cold Incidence Is Modified by Age, Smoking and Residential Neighborhood. *J. Am. Coll. Nutr.* **25**, 332–339 (2006).
394. CREA. *Linee guida per una sana alimentazione 2018*. <https://www.crea.gov.it/web/alimenti-e-nutrizione/-/linee-guida-per-una-sana-alimentazione-2018> (2019).
395. Krebs, H. A. The Sheffield Experiment on the Vitamin C Requirement of Human Adults. *Proc. Nutr. Soc.* **12**, 237–246 (1953).
396. Massie, H. R., Aiello, V. R. & Doherty, T. J. Dietary vitamin C improves the survival of mice. *Gerontology* **30**, 371–375 (1984).
397. Gorton, H. C. & Jarvis, K. The effectiveness of vitamin C in preventing and relieving the symptoms of virus-induced respiratory infections. *J. Manipulative Physiol. Ther.* **22**, 530–533 (1999).
398. van Straten, M. & Josling, P. Preventing the common cold with a vitamin C supplement: a double-blind, placebo-controlled survey. *Adv. Ther.* **19**, 151–159 (2002).
399. Kim, T. K., Lim, H. R. & Byun, J. S. Vitamin C

- supplementation reduces the odds of developing a common cold in Republic of Korea Army recruits: randomised controlled trial. *BMJ Mil. Heal.* (2020) doi:10.1136/bmjmilitary-2019-001384 PM - 32139409.
400. Liu, F., Zhu, Y., Zhang, J., Li, Y. & Peng, Z. Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicentre randomised controlled trial. *BMJ Open* **10**, e039519 (2020).
 401. Carr, A. C. & Rowe, S. The Emerging Role of Vitamin C in the Prevention and Treatment of COVID-19. *Nutrients* **12**, (2020).
 402. Abobaker, A., Alzwi, A. & Alraied, A. H. A. Overview of the possible role of vitamin C in management of COVID-19. *Pharmacol. Rep.* **72**, 1517–1528 (2020).
 403. Feyaerts, A. F. & Luyten, W. Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19? *Nutrition* **79–80**, 110948 (2020).
 404. Ginde, A. A., Mansbach, J. M. & Camargo, C. A. Association between Serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. *Arch. Intern. Med.* **169**, 384–390 (2009).
 405. Dean, C. Magnesium. *Orthomolecular.org* (2017).
 406. Beck, M. A., Levander, O. A. & Handy, J. Selenium Deficiency and Viral Infection. *J. Nutr.* **133**, 1463S-1467S (2003).
 407. Fraker, P. J., King, L. E., Laakko, T. & Vollmer, T. L. The Dynamic Link between the Integrity of the Immune System and Zinc Status. *J. Nutr.* **130**, 1399S-1406S (2000).
 408. Zojaji, H. *et al.* The efficacy of Helicobacter pylori eradication regimen with and without vitamin C supplementation. *Dig. Liver Dis.* **41**, 644–647 (2009).
 409. Fukushima, R. & Yamazaki, E. Vitamin C requirement in surgical patients. *Curr. Opin. Clin. Nutr. Metab. Care* **13**, 669–676 (2010).
 410. Cereda, E., Gini, A., Pedrolli, C. & Vanotti, A. Disease-specific, versus standard, nutritional support for the treatment of pressure ulcers in institutionalized older adults: A randomized controlled trial. *J. Am. Geriatr. Soc.* **57**, 1395–1402 (2009).
 411. Bonucci, M. Vitamina C. *Associazione Ricerca Terapie*

- Oncologiche Integrate* <https://www.artoi.it/vitamina-c/> (2020).
412. Tsovolas, K. *et al.* Acute administration of vitamin C abrogates protection from ischemic preconditioning in rabbits. *Pharmacol. Res.* **57**, 283–289 (2008).
 413. Badeaux, J. E. & Martin, J. B. Emerging Adjunctive Approach for the Treatment of Sepsis: Vitamin C and Thiamine. *Crit. Care Nurs. Clin. North Am.* **30**, 343–351 (2018).
 414. Wang, D. *et al.* Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - J. Am. Med. Assoc.* **323**, 1061–1069 (2020).
 415. Gonzalez, M. J. *et al.* High Dose Vitamin C and Influenza: A Case Report. *J Orthomol Med* **33**, (2018).
 416. Basili, S. *et al.* Intravenous Ascorbic Acid Infusion Improves Myocardial Perfusion Grade During Elective Percutaneous Coronary Intervention. Relationship With Oxidative Stress Markers. *JACC Cardiovasc. Interv.* **3**, 221–229 (2010).
 417. Dingchao, H., Zhiduan, Q., Liye, H. & Xiaodong, F. The protective effects of high-dose ascorbic acid on myocardium against reperfusion injury during and after cardiopulmonary bypass. *Thorac. Cardiovasc. Surg.* **42**, 276–278 (1994).
 418. Rodrigo, R., Prieto, J. C. & Castillo, R. Cardioprotection against ischaemia/reperfusion by vitamins C and E plus n-3 fatty acids: Molecular mechanisms and potential clinic applications. *Clinical Science* vol. 124 1–15 (2013).
 419. Saul, A. W. & Yanagisawa, A. Hospital-based Intravenous Vitamin C Treatment for Coronavirus and Related Illnesses. *Orthomolecular.org* (2020).
 420. Cameron, E., Campbell, A. & Jack, T. The orthomolecular treatment of cancer. III. Reticulum cell sarcoma: Double complete regression induced by high-dose ascorbic acid therapy. *Chem. Biol. Interact.* **11**, 387–393 (1975).
 421. Riordan, H. D. *et al.* Intravenous ascorbic acid: protocol for its application and use. *P. R. Health Sci. J.* **22**, 287–290 (2003).
 422. Drisko, J. A., Serrano, O. K., Spruce, L. R., Chen, Q. & Levine, M. Treatment of pancreatic cancer with intravenous Vitamin C: A case report. *Anticancer. Drugs* **29**, 373–379 (2018).
 423. Nielsen, T. K. *et al.* Weekly ascorbic acid infusion in

- castration-resistant prostate cancer patients: A single-arm phase II trial. *Transl. Androl. Urol.* **6**, 517–528 (2017).
424. Hemilä, H. & Chalker, E. Vitamin C for preventing and treating the common cold. *Cochrane Database Syst. Rev.* **2013**, (2013).
425. Hemilä, H. Vitamin C intake and susceptibility to the common cold. *Br. J. Nutr.* **77**, 59–72 (1997).
426. Johnston, C. S., Barkyoumb, G. M. & Schumacher, S. S. Vitamin C supplementation slightly improves physical activity levels and reduces cold incidence in men with marginal vitamin C status: A randomized controlled trial. *Nutrients* **6**, 2572–2583 (2014).
427. Hemilä, H. Vitamin C and common cold incidence: A review of studies with subjects under heavy physical stress. *Int. J. Sports Med.* **17**, 379–383 (1996).
428. Anderson, T. W., Suranyi, G. & Beaton, G. H. The effect on winter illness of large doses of vitamin C. *Can. Med. Assoc. J.* **111**, 31–36 (1974).
429. Bee, D. M. The vitamin C controversy. *Postgrad. Med.* **67**, 64 (1980).
430. Anderson, T. W., Reid, D. B. & Beaton, G. H. Vitamin C and the common cold: a double-blind trial. *Can. Med. Assoc. J.* **107**, 503–508 (1972).
431. Constantini, N. W. *et al.* The effect of vitamin C on upper respiratory infections in adolescent swimmers: A randomized trial. *Eur. J. Pediatr.* **170**, 59–63 (2011).
432. Berger, M. M. *et al.* Influence of early antioxidant supplements on clinical evolution and organ function in critically ill cardiac surgery, major trauma, and subarachnoid hemorrhage patients. *Crit. Care* **12**, (2008).
433. González, M. J. *et al.* Inhibition of human breast carcinoma cell proliferation by ascorbate and copper. *P. R. Health Sci. J.* **21**, 21–23 (2002).
434. Verrax, J. *et al.* Ascorbate potentiates the cytotoxicity of menadione leading to an oxidative stress that kills cancer cells by a non-apoptotic caspase-3 independent form of cell death. *Apoptosis* **9**, 223–233 (2004).
435. Gava, R. *Proteggersi dalle infezioni virali.* (Edizioni Salus Infirmorum, 2021).

436. Bruno, R. S. *et al.* Faster plasma vitamin E disappearance in smokers is normalized by vitamin C supplementation. *Free Radic. Biol. Med.* **40**, 689–697 (2006).
437. Diotallevi, M. *et al.* Glutathione Fine-Tunes the Innate Immune Response toward Antiviral Pathways in a Macrophage Cell Line Independently of Its Antioxidant Properties. *Front. Immunol.* **8**, 1239 (2017).
438. Amatore, D. *et al.* Glutathione increase by the n-butanoyl glutathione derivative (GSH-C4) inhibits viral replication and induces a predominant Th1 immune profile in old mice infected with influenza virus. *FASEB bioAdvances* **1**, 296–305 (2019).
439. Smith, E. M. *et al.* High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults. *Clin. Nutr.* **36**, 980–985 (2017).
440. Han, J. E. *et al.* High Dose Vitamin D Administration in Ventilated Intensive Care Unit Patients: A Pilot Double Blind Randomized Controlled Trial. *J. Clin. Transl. Endocrinol.* **4**, 59–65 (2016).
441. Hemilä, H. & Louhiala, P. Vitamin C for preventing and treating pneumonia. *Cochrane database Syst. Rev.* CD005532 (2007) doi:10.1002/14651858.CD005532.pub2 PM - 17253561.
442. Okamoto, K., Tanaka, H., Makino, Y. & Makino, I. Restoration of the glucocorticoid receptor function by the phosphodiester compound of vitamins C and E, EPC-K1 (L-ascorbic acid 2-3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl hydrogen phosphate potassium salt), via a r. *Biochem. Pharmacol.* **56**, 79–86 (1998).
443. Fujita, I., Hirano, J., Itoh, N., Nakanishi, T. & Tanaka, K. Dexamethasone induces sodium-dependant vitamin C transporter in a mouse osteoblastic cell line MC3T3-E1. *Br. J. Nutr.* **86**, 145–149 (2001).
444. Richards, E. The Politics of Therapeutic Evaluation: The Vitamin C and Cancer Controversy. *Soc. Stud. Sci.* **18**, 653–701 (1988).
445. Goodwin, J. S. & Tangum, M. R. Battling quackery: Attitudes about micronutrient supplements in American academic

- medicine. *Archives of Internal Medicine* vol. 158 2187–2191 (1998).
446. Louhiala, P. & Hemilä, H. Can CAM treatments be evidence-based? *Focus Altern. Complement. Ther.* **19**, 84–89 (2014).